REFERENCES
- Rosen L S, Gordon D, Kamniski M, et al. Long term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98: 1735–1744
- El Saghir N S, Otrock Z K, Bleik J H. Unilateral anterior uveitis complicating zoledronic acid therapy in breast cancer. BMC Cancer 2005; 6: 156
- Gilhotra J S, Gilhotra A K, Holdaway I M, Donaldson M L. Acute retinal pigment epitheliitis associated with intravenous bisphosphonate. Br J Ophthalmol 2006; 90: 798–799
- Tanvetyanon T, Stiff P J. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006; 17: 897–907
- Santini D, Vincenzi B, Caraglia M, Tonini G. A hitherto unreported high incidence of zoledronic acid-induced acute phase reaction in patients with cancer treatment-induced bone loss. Ann Oncol. 2007; 18: 201–202
- Woo T C, Joseph D J, Wilkinson R. Serious ocular complications of zoledronate. Clin Oncol (R Coll Radiol) 2006; 18: 545–546